Technical Analysis for KYKOF - Kyowa Hakko Kogyo

Grade Last Price % Change Price Change
grade A 23.0 9.52% 2.0000
KYKOF closed up 9.52 percent on Monday, February 24, 2020, on 3 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical KYKOF trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 9.52%
Narrow Range Bar Range Contraction 9.52%
Overbought Stochastic Strength 9.52%
Older signals for KYKOF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Medicine Biotechnology Cancer Pharmaceuticals Biology Chemotherapy Hypertension Allergies Vomiting Nausea Amgen Constipation Acute Lymphoblastic Leukemia Angina Pectoris Cytokines Erythropoiesis Stimulating Agent Growth Factors Secondary Hyperparathyroidism Erythropoietin Kirin Bio Chemicals Kirin Holdings Kyowa Hakko Kirin

Is KYKOF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 23.0
52 Week Low 13.25
Average Volume 6,630
200-Day Moving Average 17.5250
50-Day Moving Average 18.4144
20-Day Moving Average 19.3695
10-Day Moving Average 19.8550
Average True Range 0.7102
ADX 20.93
+DI 60.1004
-DI 31.2545
Chandelier Exit (Long, 3 ATRs ) 20.8694
Chandelier Exit (Short, 3 ATRs ) 19.0006
Upper Bollinger Band 22.1387
Lower Bollinger Band 16.6003
Percent B (%b) 1.16
BandWidth 28.5934
MACD Line 0.8178
MACD Signal Line 0.4063
MACD Histogram 0.4116
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.0000
Resistance 3 (R3) 23.0000 23.0000 23.0000
Resistance 2 (R2) 23.0000 23.0000 23.0000 23.0000
Resistance 1 (R1) 23.0000 23.0000 23.0000 23.0000 23.0000
Pivot Point 23.0000 23.0000 23.0000 23.0000 23.0000
Support 1 (S1) 23.0000 23.0000 23.0000 23.0000 23.0000
Support 2 (S2) 23.0000 23.0000 23.0000 23.0000
Support 3 (S3) 23.0000 23.0000 23.0000
Support 4 (S4) 23.0000